PYC Therapeutics' VP-001 Demonstrates Sustained Vision Improvement in RP11 Patients Following Repeat Dosing
Key Insights
PYC Therapeutics (search) reports that repeat doses of VP-0014 (search) in RP11 patients sustain the vision improvements initially seen with a single dose.
In two of three patients, the treated eye showed improvement from baseline across all three measured endpoints, outperforming the untreated eye.
The third patient experienced similar improvements in two endpoints, with the treated eye matching the untreated eye in the third endpoint.
PYC Therapeutics (search) has announced positive interim results from its repeat dose clinical trials of VP-001 for Retinitis Pigmentosa type 11 (search) (RP11). The data indicate that the improvements in vision previously observed after a single dose of VP-0014 (search) have been maintained and, in some cases, enhanced with multiple doses.
Favorable Outcomes in Repeat Dose Study
The interim update focuses on a cohort of patients receiving multiple doses of VP-001. According to PYC Therapeutics (search), two out of three patients in this cohort demonstrated that the eye treated with VP-001 outperformed the untreated eye and showed improvement from baseline across all three endpoints. The third patient also exhibited positive results, with the treated eye outperforming the untreated eye and improving from baseline in two endpoints, matching the untreated eye's performance in the third endpoint.
Safety Profile
Importantly, PYC Therapeutics (search) reported that no treatment-emergent serious adverse events have been observed in any patient treated with VP-001 to date. This includes patients who have received three doses of the highest administered dose of VP-001, suggesting a favorable safety profile for the drug candidate.
Future Updates
PYC Therapeutics (search) plans to provide a more comprehensive update on the outcomes of these multiple-dose studies in the first half of 2025. This future data release will likely include more detailed analyses of the efficacy and safety data, offering further insights into the potential of VP-001 as a treatment for RP11.